These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 209043)

  • 21. Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase.
    Bentinger M; Grünler J; Peterson E; Swiezewska E; Dallner G
    Arch Biochem Biophys; 1998 May; 353(2):191-8. PubMed ID: 9606952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of 12-cis-dehydrosqualene catalyzed by squalene synthetase.
    Nishino T; Katsuki H
    Methods Enzymol; 1985; 110():373-5. PubMed ID: 3894880
    [No Abstract]   [Full Text] [Related]  

  • 23. Purification and properties of sterol carrier protein1.
    Srikantaiah MV; Hansbury E; Loughran ED; Scallen TJ
    J Biol Chem; 1976 Sep; 251(18):5496-504. PubMed ID: 965373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzymic conversion of farnesyl pyrophosphate to squalene.
    Krishna G; Whitlock HW; Feldbruegge DH; Porter JW
    Arch Biochem Biophys; 1966 Apr; 114(1):200-15. PubMed ID: 4380977
    [No Abstract]   [Full Text] [Related]  

  • 25. The conversion of farnesyl pyrophosphate to squalene by soluble extracts of microsomes.
    ANDERSON DG; RICE MS; PORTER JW
    Biochem Biophys Res Commun; 1960 Dec; 3():591-5. PubMed ID: 13683185
    [No Abstract]   [Full Text] [Related]  

  • 26. Postnatal developmental profile of 3-hydroxy-3-methylglutaryl-CoA reductase, squalene synthetase and cholesterol 7 alpha-hydroxylase activities in the liver of domestic swine.
    Kwekkeboom J; Kempen HJ; van Voorthuizen EM; Griffioen M; Cohen LH
    Biochim Biophys Acta; 1990 Jan; 1042(1):146-9. PubMed ID: 2297519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An enzyme-bound intermediate in the conversion of farnesyl pyrophosphate to squalene.
    Krishna G; Feldbruegge DH; Porter JW
    Biochem Biophys Res Commun; 1964; 14():363-9. PubMed ID: 4284347
    [No Abstract]   [Full Text] [Related]  

  • 28. Intermembrane transfer of 5 alpha-cholest-7-en-3 beta-ol. Facilitation by supernatant protein (SCP).
    Ishibashi T; Bloch K
    J Biol Chem; 1981 Dec; 256(24):12962-7. PubMed ID: 7309744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosynthesis of presqualene pyrophosphate by liver microsomes.
    Rilling HC
    J Lipid Res; 1970 Sep; 11(5):480-5. PubMed ID: 4322765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for carrier proteins in bile acid synthesis. The effect of squalene and sterol carrier protein and albumin on the activity of 12alpha-hydroxylase.
    Grabowski GA; McCoy KE; Williams GC; Dempsey ME; Hanson RF
    Biochim Biophys Acta; 1976 Sep; 441(3):380-90. PubMed ID: 974090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-dependent changes in rat liver prenyltransferases.
    Thelin A; Runquist M; Ericsson J; Swiezewska E; Dallner G
    Mech Ageing Dev; 1994 Oct; 76(2-3):165-76. PubMed ID: 7885063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthetase.
    Biller SA; Forster C; Gordon EM; Harrity T; Scott WA; Ciosek CP
    J Med Chem; 1988 Oct; 31(10):1869-71. PubMed ID: 3172121
    [No Abstract]   [Full Text] [Related]  

  • 33. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents.
    Cohen LH; Valentijn AR; Roodenburg L; Van Leeuwen RE; Huisman RH; Lutz RJ; Van der Marel GA; Van Boom JH
    Biochem Pharmacol; 1995 Mar; 49(6):839-45. PubMed ID: 7702642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulations in hepatic branch-point enzymes involved in isoprenoid biosynthesis upon dietary and drug treatments of rats.
    Andersson M; Ericsson J; Appelkvist EL; Schedin S; Chojnacki T; Dallner G
    Biochim Biophys Acta; 1994 Aug; 1214(1):79-87. PubMed ID: 8068731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of squalene synthetase and squalene epoxidase activities in Saccharomyces cerevisiae.
    M'Baya B; Fegueur M; Servouse M; Karst F
    Lipids; 1989 Dec; 24(12):1020-3. PubMed ID: 2693869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Squalene synthetase activity in human fibroblasts: regulation via the low density lipoprotein receptor.
    Faust JR; Goldstein JL; Brown MS
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5018-22. PubMed ID: 228272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
    Hohl RJ; Lewis KA; Cermak DM; Wiemer DF
    Lipids; 1998 Jan; 33(1):39-46. PubMed ID: 9470172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.
    Amin D; Cornell SA; Perrone MH; Bilder GE
    Arzneimittelforschung; 1996 Aug; 46(8):759-62. PubMed ID: 9125274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes.
    Bansal VS; Vaidya S
    Arch Biochem Biophys; 1994 Dec; 315(2):393-9. PubMed ID: 7986083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.